Elemer Piros
Stock Analyst at LUCID CAPITAL MARKETS
(2.75)
# 1,919
Out of 4,944 analysts
108
Total ratings
39.81%
Success rate
6.98%
Average return
Main Sectors:
Stocks Rated by Elemer Piros
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BTAI BioXcel Therapeutics | Reiterates: Buy | $66 | $5.60 | +1,078.57% | 2 | Jul 15, 2025 | |
| FBLG FibroBiologics | Initiates: Buy | $12 | $0.59 | +1,936.66% | 1 | Dec 12, 2024 | |
| THAR Tharimmune | Initiates: Buy | $17 | $1.32 | +1,187.88% | 1 | Dec 6, 2024 | |
| QNCX Quince Therapeutics | Initiates: Buy | $11 | $1.72 | +539.53% | 1 | Oct 29, 2024 | |
| MNPR Monopar Therapeutics | Initiates: Buy | $50 | $33.51 | +49.21% | 6 | Oct 11, 2024 | |
| MIRA MIRA Pharmaceuticals | Initiates: Buy | $17 | $1.49 | +1,040.94% | 1 | Sep 30, 2024 | |
| ATHA Athira Pharma | Initiates: Buy | $22 | $0.39 | +5,541.03% | 1 | Aug 19, 2024 | |
| SAVA Cassava Sciences | Reiterates: Buy | $107 | $2.28 | +4,592.98% | 1 | Aug 8, 2024 | |
| CGTX Cognition Therapeutics | Reiterates: Buy | $14 | $1.22 | +1,047.54% | 1 | Jul 2, 2024 | |
| ANVS Annovis Bio | Reiterates: Buy | $67 | $2.70 | +2,381.48% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $43 | $3.13 | +1,273.80% | 1 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $6.20 | +190.32% | 7 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $7.5 | $1.30 | +476.92% | 3 | Sep 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $15 | $4.05 | +270.37% | 8 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $21 | $9.97 | +110.63% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 | $4.29 | +785.78% | 9 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $0.72 | +5,471.03% | 2 | Jul 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $4.41 | +1,033.79% | 5 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $114 | $7.60 | +1,400.00% | 3 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $200 | $3.65 | +5,379.45% | 6 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $3.41 | +574.49% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $33 | $12.56 | +162.74% | 3 | Mar 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $40 | $26.58 | +50.49% | 7 | Apr 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $1.48 | +2,400.00% | 1 | Dec 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $38 → $32 | $6.00 | +433.33% | 2 | Jun 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $77 | $19.21 | +300.83% | 2 | Dec 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $1.90 | +3,584.21% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $9.59 | - | 5 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $50 | $19.99 | +150.13% | 5 | Nov 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $33 | $5.37 | +514.53% | 2 | Oct 22, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $10.83 | - | 3 | Jul 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $26 | $4.27 | +508.90% | 3 | May 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $149.36 | -81.25% | 1 | Sep 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $525 → $850 | $6.56 | +12,857.32% | 1 | Oct 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $21 | $12.50 | +68.00% | 2 | Jul 12, 2017 |
BioXcel Therapeutics
Jul 15, 2025
Reiterates: Buy
Price Target: $66
Current: $5.60
Upside: +1,078.57%
FibroBiologics
Dec 12, 2024
Initiates: Buy
Price Target: $12
Current: $0.59
Upside: +1,936.66%
Tharimmune
Dec 6, 2024
Initiates: Buy
Price Target: $17
Current: $1.32
Upside: +1,187.88%
Quince Therapeutics
Oct 29, 2024
Initiates: Buy
Price Target: $11
Current: $1.72
Upside: +539.53%
Monopar Therapeutics
Oct 11, 2024
Initiates: Buy
Price Target: $50
Current: $33.51
Upside: +49.21%
MIRA Pharmaceuticals
Sep 30, 2024
Initiates: Buy
Price Target: $17
Current: $1.49
Upside: +1,040.94%
Athira Pharma
Aug 19, 2024
Initiates: Buy
Price Target: $22
Current: $0.39
Upside: +5,541.03%
Cassava Sciences
Aug 8, 2024
Reiterates: Buy
Price Target: $107
Current: $2.28
Upside: +4,592.98%
Cognition Therapeutics
Jul 2, 2024
Reiterates: Buy
Price Target: $14
Current: $1.22
Upside: +1,047.54%
Annovis Bio
Jul 2, 2024
Reiterates: Buy
Price Target: $67
Current: $2.70
Upside: +2,381.48%
Jun 21, 2024
Initiates: Buy
Price Target: $43
Current: $3.13
Upside: +1,273.80%
Jun 13, 2024
Initiates: Buy
Price Target: $18
Current: $6.20
Upside: +190.32%
Sep 14, 2023
Maintains: Buy
Price Target: $12 → $7.5
Current: $1.30
Upside: +476.92%
Aug 9, 2023
Reiterates: Buy
Price Target: $15
Current: $4.05
Upside: +270.37%
Aug 4, 2023
Reiterates: Buy
Price Target: $21
Current: $9.97
Upside: +110.63%
Aug 3, 2023
Reiterates: Buy
Price Target: $38
Current: $4.29
Upside: +785.78%
Jul 10, 2023
Reiterates: Buy
Price Target: $40
Current: $0.72
Upside: +5,471.03%
Jun 30, 2023
Reiterates: Buy
Price Target: $50
Current: $4.41
Upside: +1,033.79%
Jun 20, 2023
Reiterates: Buy
Price Target: $114
Current: $7.60
Upside: +1,400.00%
Jun 20, 2023
Maintains: Buy
Price Target: $260 → $200
Current: $3.65
Upside: +5,379.45%
May 16, 2023
Reiterates: Buy
Price Target: $23
Current: $3.41
Upside: +574.49%
Mar 2, 2023
Reiterates: Buy
Price Target: $33
Current: $12.56
Upside: +162.74%
Apr 14, 2022
Downgrades: Sell
Price Target: $40
Current: $26.58
Upside: +50.49%
Dec 1, 2021
Initiates: Buy
Price Target: $37
Current: $1.48
Upside: +2,400.00%
Jun 30, 2021
Maintains: Buy
Price Target: $38 → $32
Current: $6.00
Upside: +433.33%
Dec 23, 2020
Downgrades: Sell
Price Target: $77
Current: $19.21
Upside: +300.83%
Oct 12, 2020
Initiates: Buy
Price Target: $70
Current: $1.90
Upside: +3,584.21%
Sep 8, 2020
Downgrades: Neutral
Price Target: n/a
Current: $9.59
Upside: -
Nov 19, 2019
Maintains: Neutral
Price Target: $24 → $50
Current: $19.99
Upside: +150.13%
Oct 22, 2019
Assumes: Overweight
Price Target: $33
Current: $5.37
Upside: +514.53%
Jul 11, 2019
Upgrades: Overweight
Price Target: n/a
Current: $10.83
Upside: -
May 6, 2019
Initiates: Overweight
Price Target: $26
Current: $4.27
Upside: +508.90%
Sep 11, 2018
Initiates: Overweight
Price Target: $28
Current: $149.36
Upside: -81.25%
Oct 12, 2017
Maintains: Overweight
Price Target: $525 → $850
Current: $6.56
Upside: +12,857.32%
Jul 12, 2017
Maintains: Overweight
Price Target: $35 → $21
Current: $12.50
Upside: +68.00%